[go: up one dir, main page]

CL2019001750A1 - Derivados de alcoxi bis-heteroarilo como moduladores de la agregación de proteínas. - Google Patents

Derivados de alcoxi bis-heteroarilo como moduladores de la agregación de proteínas.

Info

Publication number
CL2019001750A1
CL2019001750A1 CL2019001750A CL2019001750A CL2019001750A1 CL 2019001750 A1 CL2019001750 A1 CL 2019001750A1 CL 2019001750 A CL2019001750 A CL 2019001750A CL 2019001750 A CL2019001750 A CL 2019001750A CL 2019001750 A1 CL2019001750 A1 CL 2019001750A1
Authority
CL
Chile
Prior art keywords
disease
protein aggregation
french
modulators
heteroaryl derivatives
Prior art date
Application number
CL2019001750A
Other languages
English (en)
Inventor
Adrian Hall
Malcolm Maccoss
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CL2019001750A1 publication Critical patent/CL2019001750A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A CIERTOS COMPUESTOS DE BISHETEROARILO, A LAS COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y A LOS MÉTODOS PARA USARLOS, INCLUIDOS LOS MÉTODOS PARA PREVENIR, REVERTIR, DESACELERAR O INHIBIR LA AGREGACIÓN DE PROTEÍNAS, Y A LOS MÉTODOS PARA TRATAR ENFERMEDADES QUE ESTÁN ASOCIADAS CON LA AGREGACIÓN DE PROTEÍNAS, INCLUYENDO LAS ENFERMEDADES NEURODEGENERATIVAS TALES COMO LA ENFERMEDAD DE PARKINSON, LA ENFERMEDAD DE ALZHEIMER, LA ENFERMEDAD DE LOS CUERPOS DE LEWY, LA ENFERMEDAD DE PARKINSON CON DEMENCIA, LA DEMENCIA FRONTO-TEMPORAL, LA ENFERMEDAD DE HUNTINGTON, LA ESCLEROSIS LATERAL AMIOTRÓFICA, LA ATROFIA MULTISISTÉMICA Y EL CÁNCER, INCLUIDO EL MELANOMA.
CL2019001750A 2017-01-26 2019-06-21 Derivados de alcoxi bis-heteroarilo como moduladores de la agregación de proteínas. CL2019001750A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17153210 2017-01-26

Publications (1)

Publication Number Publication Date
CL2019001750A1 true CL2019001750A1 (es) 2019-11-22

Family

ID=57906525

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001750A CL2019001750A1 (es) 2017-01-26 2019-06-21 Derivados de alcoxi bis-heteroarilo como moduladores de la agregación de proteínas.

Country Status (16)

Country Link
US (1) US11091474B2 (es)
EP (1) EP3573981B1 (es)
JP (1) JP7100042B2 (es)
KR (1) KR20190112031A (es)
CN (1) CN110191885B (es)
AU (1) AU2018213886A1 (es)
BR (1) BR112019011931A2 (es)
CL (1) CL2019001750A1 (es)
CO (1) CO2019007833A2 (es)
EA (1) EA201991753A1 (es)
ES (1) ES2918048T3 (es)
IL (1) IL268003A (es)
MA (1) MA47369A (es)
MX (1) MX2019007054A (es)
RU (1) RU2019126164A (es)
WO (1) WO2018138085A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019011932A2 (pt) * 2017-01-26 2019-10-29 Ucb Biopharma Sprl derivados de bis-heteroarila como moduladores da agregação de proteína
CN113214289B (zh) * 2020-01-21 2022-10-28 瀚远医药有限公司 5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用
CN118488951A (zh) * 2021-12-27 2024-08-13 上海京新生物医药有限公司 作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物
WO2025002040A1 (zh) * 2023-06-25 2025-01-02 上海京新生物医药有限公司 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
EP2513090A1 (en) 2009-12-16 2012-10-24 Neuropore Therapies, Inc. Compound suitable for the treatment of synucleopathies
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases
NZ631388A (en) 2012-03-28 2016-01-29 Neuropore Therapies Inc Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
KR20150031481A (ko) 2012-07-16 2015-03-24 뉴로포레 테라피스, 인코포레이티드 단백질 응집 저해제로서의 디- 및 트리-헤테로아릴 유도체
RS57533B1 (sr) * 2014-01-29 2018-10-31 Ucb Biopharma Sprl Heteroaril amidi kao inhibitori proteinske agregacije
WO2017020010A1 (en) 2015-07-29 2017-02-02 Neuropore Therapies, Inc. Bis-heteroaryl derivatives as modulators of protein aggregation
BR112019011932A2 (pt) * 2017-01-26 2019-10-29 Ucb Biopharma Sprl derivados de bis-heteroarila como moduladores da agregação de proteína
ES2884145T3 (es) * 2017-01-26 2021-12-10 UCB Biopharma SRL Derivados bicíclicos de bis-heteroarilo como moduladores de la agregación de proteínas

Also Published As

Publication number Publication date
EP3573981A1 (en) 2019-12-04
EA201991753A1 (ru) 2020-01-14
RU2019126164A (ru) 2021-02-26
CA3048946A1 (en) 2018-08-02
WO2018138085A1 (en) 2018-08-02
MX2019007054A (es) 2019-08-29
MA47369A (fr) 2019-12-04
AU2018213886A1 (en) 2019-07-25
CO2019007833A2 (es) 2019-08-20
US11091474B2 (en) 2021-08-17
US20200291013A1 (en) 2020-09-17
EP3573981B1 (en) 2022-03-16
IL268003A (en) 2019-09-26
ES2918048T3 (es) 2022-07-13
JP7100042B2 (ja) 2022-07-12
BR112019011931A2 (pt) 2019-10-29
JP2020505368A (ja) 2020-02-20
CN110191885B (zh) 2023-05-16
CN110191885A (zh) 2019-08-30
KR20190112031A (ko) 2019-10-02

Similar Documents

Publication Publication Date Title
CO2019007835A2 (es) Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
CO2019007830A2 (es) Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas
CR20160394A (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CL2019001750A1 (es) Derivados de alcoxi bis-heteroarilo como moduladores de la agregación de proteínas.
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
UY36077A (es) Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
CO2017012995A2 (es) Derivados análogos de heteroarilos/arilo actvos como reguladores nrf2 y composiciones farmacéuticas de los mismos
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
CO2018009889A2 (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
CL2017003127A1 (es) Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico m1 colinergico.
CL2016002346A1 (es) Composiciones para modular la expresión de ataxina 2
MX2015011533A (es) Derivados de triazolona de piridinilo y piridinilo fusionado.
EP3328379A4 (en) BIS-HETEROARYL DERIVATIVES AS MODULATORS OF THE PROTEIN AGGREGATION
DOP2017000117A (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CL2016002677A1 (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1.
CL2017000244A1 (es) Formulaciones de compuestos biológicos para instilación intravesical.
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
MX2018007511A (es) Compuestos de alquinil dihidroquinolina sulfonamida.
MX2018007432A (es) Compuestos de dihidroquinolinsulfonamida de alquilo.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7